← All trials
NCT05240612
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Feb 15, 2022
- Last posted
- May 17, 2022
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mitsubishi TanabeLead sponsor
- Mitsubishi TanabeStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.